Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Trans Health Research Group, Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia.
Intern Med J. 2024 Sep;54(9):1450-1457. doi: 10.1111/imj.16413. Epub 2024 Jul 26.
Gender-affirming hormone therapy (GAHT) is used by many transgender and gender-diverse adults to align physical characteristics with their gender identity, reduce gender incongruence and improve psychological functioning. This narrative review provides an overview of the initiation and monitoring of GAHT in an Australian context. Trans individuals treated with testosterone typically receive standard testosterone doses and formulations recommended for cisgender men, whereas those receiving estradiol GAHT are typically treated with estradiol in combination with an anti-androgen in those without orchidectomy. Proactive monitoring and mitigation of cardiovascular risk factors is pertinent in all transgender and gender-diverse adults and bone health is an important consideration in those using estradiol GAHT.
性别肯定激素疗法（GAHT）被许多跨性别和性别多样化的成年人用于使身体特征与他们的性别认同一致，减少性别不一致，并改善心理功能。本叙述性综述提供了澳大利亚背景下 GAHT 的启动和监测概述。接受睾丸素治疗的跨性别个体通常接受推荐给顺性别男性的标准睾丸素剂量和制剂，而接受雌二醇 GAHT 的个体通常在没有去势的情况下与抗雄激素联合使用雌二醇进行治疗。主动监测和降低心血管风险因素在所有跨性别和性别多样化的成年人中都很重要，而在使用雌二醇 GAHT 的成年人中，骨骼健康是一个重要的考虑因素。
